Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methylcrotonoyl-CoA carboxylase subunit beta is the beta chain of the mitochondrial enzyme methylcrotonoyl-CoA carboxylase, which catalyzes the ATP-dependent biotin-requiring conversion of 3-methylcrotonoyl-CoA to 3-methylglutaconyl-CoA. This reaction represents the fourth step in the breakdown pathway for leucine, an essential branched-chain amino acid. The functional holoenzyme consists of six alpha and six beta subunits encoded by MCCC1 and MCCC2, respectively. Deficiency due to genetic mutations results in an inherited disorder characterized by impaired protein catabolism leading to toxic metabolite accumulation and clinical symptoms such as vomiting, metabolic acidosis, hypoglycemia, and low plasma carnitine levels. The enzyme plays a critical role in energy production from dietary proteins but is not currently considered a direct therapeutic drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methylcrotonoyl-CoA carboxylase subunit beta (MCCB).